Nasdaq’s determination is based on the Company meeting all other applicable requirements for listing on the Nasdaq Capital Market, with the exception of the bid price requirement, and the Company’s ...

From the brink of Nasdaq delisting last year due to non-compliance with the minimum bid price rule, this clinical-stage biotechnology ...

Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies ...

Belite Bio is a biotech firm specializing in innovative therapies for retinal degenerative eye diseases with high unmet needs ...

Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

Eton Pharmaceuticals, Inc ("Eton" or the "Company") (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments ...

Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compared to Q4 2023.Pipeline progress included the approval ...

Some food labels designed to nudge Americans toward healthier food choices can have the opposite effect, new University of ...

Actinogen Medical Limited (ASX: ACW) announces that the World Health Organization (WHO) has granted the nonproprietary name of ’emestedastat’ to Actinogen for its Xanamem ® /UE2343 once-a-day small ...